Accustem Sciences Inc
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. It offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. The company also provides StemPrintER, a 20-gene prognostic assay to … Read more
Accustem Sciences Inc (ACUT) - Total Liabilities
Latest total liabilities as of September 2025: $4.48 Million USD
Based on the latest financial reports, Accustem Sciences Inc (ACUT) has total liabilities worth $4.48 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Accustem Sciences Inc - Total Liabilities Trend (2022–2024)
This chart illustrates how Accustem Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Accustem Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Accustem Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tony G Co-Investment Holdings Ltd
PINK:BGRDF
|
USA | $868.47K |
|
PHI Group Inc
PINK:PHIL
|
USA | $11.68 Million |
|
Hanover House Inc.
PINK:HHSE
|
USA | $3.53 Million |
|
Diamond Estates Wines & Spirits Inc
PINK:DWWEF
|
USA | $18.16 Million |
|
Roctool
PA:ALROC
|
France | €3.91 Million |
|
Kein Hing International Bhd
KLSE:7199
|
Malaysia | RM99.98 Million |
|
Lee Swee Kiat Group Bhd
KLSE:8079
|
Malaysia | RM37.03 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down Accustem Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Accustem Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Accustem Sciences Inc (2022–2024)
The table below shows the annual total liabilities of Accustem Sciences Inc from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.36 Million | +49.82% |
| 2023-12-31 | $2.25 Million | +108.06% |
| 2022-12-31 | $1.08 Million | -- |